Journal of Alzheimer s Disease, Journal Year: 2024, Volume and Issue: 102(1), P. 99 - 109
Published: Oct. 15, 2024
Recent research suggests that selective serotonin reuptake inhibitors (SSRIs) may reduce mortality in COVID-19 patients; however, into their benefits for elderly Alzheimer's disease (AD) patients remains limited.
Language: Английский
Computational and Structural Biotechnology Journal, Journal Year: 2024, Volume and Issue: 24, P. 115 - 125
Published: Jan. 9, 2024
BackgroundPost-acute sequelae of COVID-19 (PASC) produce significant morbidity, prompting evaluation interventions that might lower risk. Selective serotonin reuptake inhibitors (SSRIs) potentially could modulate risk PASC via their central, hypothesized immunomodulatory, and/or antiplatelet properties although clinical trial data are lacking.Materials and MethodsThis retrospective study was conducted leveraging real-world within the National COVID Cohort Collaborative (N3C) to evaluate whether SSRIs with agonist activity at sigma-1 receptor (S1R) PASC, since agonism this may serve as a mechanism by which attenuate an inflammatory response. Additionally, determine potential benefit be traced S1R agonism. Presumed defined based on computable phenotype trained U09.9 ICD-10 diagnosis code.ResultsOf 17,908 patients identified, 1521 were exposed baseline SSRI, 1803 non-S1R 14,584 neither. Using inverse probability weighting Poisson regression, relative (RR) assessed.A 29% reduction in RR (0.704 [95% CI, 0.58-0.85]; P = 4 ×10-4) seen among who received SSRI compared unexposed 21% those receiving without (0.79 0.67 - 0.93]; 0.005).Thus, reported associated decrease PASC.
Language: Английский
Citations
15
Journal of Psychosomatic Research, Journal Year: 2025, Volume and Issue: 190, P. 112053 - 112053
Published: Feb. 13, 2025
Language: Английский
Citations
0
Clinical Microbiology and Infection, Journal Year: 2024, Volume and Issue: 30(6), P. 836 - 837
Published: Feb. 10, 2024
Language: Английский
Citations
2
Journal of Psychopharmacology, Journal Year: 2024, Volume and Issue: 38(4), P. 395 - 403
Published: March 13, 2024
Background: Due to non-consistent reports in the literature, there are uncertainties about potential benefits and harms of selective serotonin reuptake inhibitors (SSRIs) patients with Coronavirus disease 2019 (COVID-19). Aim: To investigate associations SSRIs clinical characteristics unwanted outcomes among real-life severe critical COVID-19 their relationship remdesivir (RDV) use. Methods: This retrospective cohort study evaluated a total 1558 white race treated tertiary center institution, them 779 RDV 1:1 case-matched patients. Results: A 78 (5%) were exposed during hospitalization, similarly distributed matched (5.1 4.9%). No significant SSRI use age, sex, comorbidity burden, severity present either two cohorts ( p > 0.05 for all analyses). In multivariate analyses adjusted clinically meaningful variables, was significantly associated higher mortality (adjusted odds ratio (aOR) 2.0, = 0.049) (aOR 2.22, 0.044) risk mechanical-ventilation 2.57, 0.006), venous-thromboembolism 3.69, 0.007), bacteremia Conclusions: Adverse might be potentiated by use, interactions between these drug classes exist. Although our findings raise important considerations practice, they limited nature study, lack ethnic diversity, unmeasured confounding factors. Future studies exploring underlying biological mechanisms needed.
Language: Английский
Citations
2
Fortschritte der Neurologie · Psychiatrie, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 23, 2024
Introduction Preclinically, fluvoxamine and other antidepressants (AD) exerted antiviral anti-inflammatory properties also against SARS-COV-2. Therfore, It makes sense to test the clinical effect of AD COVID-19 Long COVID.
Language: Английский
Citations
1
Expert Opinion on Drug Metabolism & Toxicology, Journal Year: 2023, Volume and Issue: 19(12), P. 937 - 950
Published: Nov. 7, 2023
Antidepressants are widely used for the pharmacological treatment of anxiety and mood disorders. Since eruption SARS-COV-2 pandemic later development targeted treatments against COVID-19, inevitably many patients receive antidepressants as well COVID-19 COVID-19. Co-administration with therapeutics has potential drug-drug interactions, varying severity clinical significance.
Language: Английский
Citations
3
Clinical Microbiology and Infection, Journal Year: 2023, Volume and Issue: 30(2), P. 151 - 151
Published: Oct. 11, 2023
Language: Английский
Citations
1
Human Psychopharmacology Clinical and Experimental, Journal Year: 2023, Volume and Issue: unknown
Published: Dec. 7, 2023
Abstract Introduction Relationships between inflammation and mood have been observed in terms of pro‐inflammatory effects induced by depressive conditions and, parallel, an antidepressant‐induced favorable effect on the recovery inflammatory states. Selective serotonin reuptake inhibitor (SSRI) drugs were hypothesized to improve prognosis COVID‐19 pneumonia, a typical acute inflammation, decreased mortality rate cytokine serum levels. Methods The medical records pneumonia inpatients at Careggi University Hospital (Florence) analyzed for Interleukin 6 (IL‐6) after admission over period 22 months. Medical patients treated not discontinued until discharge with SSRI or vortioxetine identified. Two groups, one antidepressants, other treated, evaluated according mentioned parameters. Multiple linear regression logistic performed. Results entire sample composed 1236 (recovered 77.1%, deceased 22.9%). group ( n = 107) had better than untreated spite age comorbidity both being greater group. Correspondingly, IL‐6 levels significantly lower p < 0.01) group, every comparison. Conclusions Outcomes this study support hypothesis influence some antidepressants COVID‐19, possibly mediated modulation. Reduction action was confirmed.
Language: Английский
Citations
1
Clinical Microbiology and Infection, Journal Year: 2024, Volume and Issue: 30(6), P. 838 - 839
Published: Feb. 29, 2024
Language: Английский
Citations
0
Pharmacology, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 8
Published: July 31, 2024
<b><i>Introduction:</i></b> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a causative agent of disease 2019 (COVID-19), very contagious systemic dominantly affecting the tract. Recent findings oppose earlier suggestions that selective serotonin reuptake inhibitors (SSRIs) might be protective during SARS-CoV-2 infection, prompting current study. <b><i>Methods:</i></b> The institutional registry tertiary referral center was retrospectively evaluated for SSRI use and associated clinical outcomes among hospitalized COVID-19 patients with mostly severe critical disease. <b><i>Results:</i></b> Among 1,558 patients, there were 78 (5%) exposed to hospitalization. users in comparison non-users did not significantly differ their demographic characteristics, comorbidity profile or severity symptoms inflammatory response at admission. In multivariate analyses adjusted clinically meaningful variables, higher risks death, mechanical ventilation, intensive care unit treatment, bacteremia, whereas no significant relationship venous, arterial thrombosis, major bleeding present. Patients less initial presentation, lower burden, platelet count, cumulative presence hyperlipidemia, atrial fibrillation, chronic heart failure nonexposed acetylsalicylic-acid had mortality use. <b><i>Conclusions:</i></b> Findings study validate but also report tendency deterioration, bacteremia patients. These suggest potential contribution cardiovascular comorbidities detrimental course
Language: Английский
Citations
0